首页> 外文期刊>The aging male: the official journal of the International Society for the Study of the Aging Male >Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism.
【24h】

Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism.

机译:患有迟发性性腺功能减退症状的患者在服用saikokaryuukotsuboreito或睾丸激素后细胞因子水平的变化。

获取原文
获取原文并翻译 | 示例
       

摘要

The purpose of this study was to evaluate plasma cytokine levels after treatment with saikokaryukotsuboreito (SKRBT), which is a herbal medicine, or androgen replacement treatment (ART), for patients with late-onset hypogonadism (LOH)-related symptoms. Thirty-one patients over 40 years of age with LOH-related symptoms were included in this study. SKRBT was given orally three times daily to a total of 7.5 g/day for 15 eugonadal patients and ART was give to 16 hypogonadal patients by intramuscular injection of testosterone enanthate at 125 mg each time every 2 weeks. Plasma levels of testosterone and 18 cytokines, as well as LOH-related symptoms scored according to the Aging Males' Symptoms (AMS) scale, were compared before and more than 2 months after treatment. In the ART group, the total AMS score was decreased and testosterone was increased significantly after treatment. No cytokine variables were altered significantly after the treatment. In the SKRBT group, although the total AMS score was significantly decreased, testosterone did not change. From the evaluation of cytokines, a significant increase was found in interleukin (IL)- 8, IL-13, interferon-gamma and tumour necrosis factor-alpha. We conclude that SKRBT might improve LOH-related symptoms in eugonadal patients through the beneficial effect of cytokines, a mechanism that is quite different from ART.
机译:这项研究的目的是评估用saikokaryukotsuboreito(SKRBT)(一种草药或雄激素替代治疗(ART))治疗的迟发性性腺功能减退(LOH)相关症状患者的血浆细胞因子水平。本研究纳入了31位40岁以上的LOH相关症状患者。每天3次口服SKRBT,共15例性腺癌患者,总剂量为7.5 g /天,并通过每2周每次肌注125 mg庚酸睾丸酮对16例性腺功能减退患者进行ART。在治疗前和治疗后两个月比较了血浆睾丸激素和18种细胞因子的水平,以及根据老年男性症状(AMS)量表评分的LOH相关症状。在ART组中,治疗后AMS总分降低,睾丸激素明显升高。治疗后,没有任何细胞因子变量发生明显改变。在SKRBT组中,尽管AMS的总得分明显降低,但睾丸激素没有变化。通过细胞因子的评估,发现白介素(IL)-8,IL-13,干扰素-γ和肿瘤坏死因子-α显着增加。我们得出的结论是,SKRBT可能通过细胞因子的有益作用改善性腺疾病患者的LOH相关症状,这种机制与ART完全不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号